Literature DB >> 3481337

Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors.

H Marçais-Collado1, G Uchida, J Costentin, J C Schwartz, J M Lecomte.   

Abstract

Thiorphan and acetorphan, two potent inhibitors of enkephalinase (EC 3.4.24.11 membrane-metalloendopeptidase) significantly reduced the castor oil-induced diarrhea in rats when administered intravenously (or orally, for acetorphan) but not when administered intracerebroventricularly. These effects were more marked during the 90 min period following the castor oil challenge but were still significant up to 4-8 h after the latter. Acetorphan was about 6 times more potent than thiorphan. The antidiarrheal activity of both compounds was completely prevented in rats receiving naloxone subcutaneously but not intracerebroventricularly (in the case of thiorphan). In contrast to loperamide, a peripherally acting opiate receptor agonist, the enkephalinase inhibitors did not significantly reduce gastrointestinal transit as measured in the charcoal meal test. The antidiarrheal activity of enkephalinase inhibitors therefore seems attributable to protection of endogenous opioids, presumably outside the brain, and to reduction of intestinal secretion rather than transit.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481337     DOI: 10.1016/0014-2999(87)90510-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Racecadotril.

Authors:  A J Matheson; S Noble
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea.

Authors:  P Baumer; E Danquechin Dorval; J Bertrand; J M Vetel; J C Schwartz; J M Lecomte
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

Review 3.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

4.  Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial.

Authors:  N H Alam; H Ashraf; W A Khan; M M Karim; G J Fuchs
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

5.  Pre- and post-natal ontogeny of neutral endopeptidase 24-11 ('enkephalinase') studied by in vitro autoradiography in the rat.

Authors:  I Dutriez; N Salès; M C Fournié-Zaluski; B P Roques
Journal:  Experientia       Date:  1992-03-15

6.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

7.  Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea.

Authors:  David W Griggs; Michael J Prinsen; Jonathan Oliva; Mary A Campbell; Stacy D Arnett; Deena Tajfirouz; Peter G Ruminski; Ying Yu; Brian R Bond; Yuhua Ji; Georg Neckermann; Robert K M Choy; Eugenio de Hostos; Marvin J Meyers
Journal:  J Pharmacol Exp Ther       Date:  2016-02-23       Impact factor: 4.030

Review 8.  A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.

Authors:  Wolfgang Fischbach; Viola Andresen; Marion Eberlin; Tobias Mueck; Peter Layer
Journal:  Front Med (Lausanne)       Date:  2016-10-14

9.  Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.

Authors:  Wakako Fujita; Ivone Gomes; Leonard S Dove; David Prohaska; Gail McIntyre; Lakshmi A Devi
Journal:  Biochem Pharmacol       Date:  2014-09-28       Impact factor: 5.858

Review 10.  Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials.

Authors:  Marion Eberlin; Min Chen; Tobias Mueck; Jan Däbritz
Journal:  BMC Pediatr       Date:  2018-04-03       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.